Pittsburgh, Pennsylvania, USA, November 17, 2026
Viatris Inc. has announced the successful completion of its acquisition of Pacira BioSciences, Inc., a leading biopharmaceutical company specializing in innovative non-opioid pain management therapies. The acquisition marks a significant milestone in Viatris’ strategy to strengthen its U.S. innovative medicines business and expand its presence in the specialty pharmaceutical market. Originally announced on October 8, 2026, the transaction brings together two complementary pharmaceutical portfolios, commercial capabilities and research and development expertise. Through this acquisition, Pacira becomes a wholly owned subsidiary of Viatris, enabling the combined organization to strengthen its position in non-opioid pain management and expand opportunities across selected international markets. The transaction involves a cash offer of $36.50 per share, representing an aggregate equity value of approximately $1.65 billion when initially announced. Viatris expects the acquisition to contribute approximately $90 million to $100 million in total revenue for the remainder of 2026, covering the period from November 17 through December 31.
Viatris Completes Pacira Acquisition Through Tender Offer
The acquisition was finalized following the successful completion of Viatris’ tender offer to purchase all outstanding shares of Pacira BioSciences. The tender offer expired shortly after 11:59 p.m. Eastern Time on November 16, 2026. According to the company, approximately 32,929,780 Pacira shares were validly tendered and not withdrawn, representing approximately 66.46% of the company’s outstanding shares. After all applicable conditions were satisfied or waived on November 17, Viatris’ wholly owned subsidiary, Peach Purchaser Sub Inc., accepted the tendered shares for payment. Following the tender offer, the acquisition was completed through a merger under Section 251(h) of the General Corporation Law of the State of Delaware, without requiring a separate vote by Pacira stockholders. Pacira continued as the surviving corporation and became a wholly owned subsidiary of Viatris. The remaining outstanding shares that were not tendered were also converted into the right to receive the same cash consideration of $36.50 per share, subject to the transaction terms. Following completion, Pacira shares are expected to be delisted from the Nasdaq Global Select Market. The successful closing concludes the acquisition process announced by both companies in October and formally integrates Pacira into Viatris’ pharmaceutical business.
EXPAREL and ZILRETTA Strengthen Non-Opioid Pain Portfolio
A major strategic advantage of the acquisition is the addition of two established, patent-protected pharmaceutical products to Viatris’ portfolio: EXPAREL® (bupivacaine liposome injectable suspension) and ZILRETTA® (triamcinolone acetonide extended-release injectable suspension). EXPAREL is used for managing acute postsurgical pain, while ZILRETTA is indicated for managing osteoarthritis knee pain. Both products strengthen Viatris’ presence in the growing non-opioid pain management market, where healthcare professionals continue to seek additional treatment options that can help address pain without relying exclusively on opioid-based medications. The products also provide Viatris with established commercial opportunities in the United States and potential opportunities to expand their reach into selected international markets through its existing global infrastructure. The acquisition is also expected to complement Viatris’ fast-acting meloxicam opportunity, creating additional strategic opportunities across its pain management portfolio. By combining Pacira’s marketed products with Viatris’ intellectual property expertise, commercial infrastructure and established pharmaceutical capabilities, the company aims to maximize the long-term value of these medicines and support broader market development.
Acquisition Expands Research and Development Capabilities
Beyond the addition of marketed medicines, the acquisition brings important commercial, medical affairs, market access and global research and development capabilities into Viatris’ innovative medicines business. Pacira’s expertise in non-opioid pain management and specialty-driven therapeutic areas is expected to complement Viatris’ existing operations and development pipeline. The combined organization aims to identify opportunities for product development, lifecycle management and international commercialization while strengthening its ability to address areas of significant unmet medical need. Viatris CEO Scott A. Smith described the transaction as an important milestone in executing the company’s strategy to strengthen its U.S. innovative medicines business and establish a stronger position in non-opioid pain management. The company also expects the acquisition to support its longer-term revenue and earnings growth objectives. However, the anticipated commercial benefits, operational efficiencies and potential synergies will depend on successful integration and execution of the combined business strategy. Overall, the completion of the Pacira BioSciences acquisition represents a major strategic expansion for Viatris, strengthening its innovative pharmaceutical portfolio and positioning the company for further growth in non-opioid pain management.
Source: Viatris, Pacira BioSciences press release



